Literature DB >> 8705907

Prevalence of factor V Leiden in a Canadian blood donor population.

D H Lee1, P A Henderson, M A Blajchman.   

Abstract

OBJECTIVE: To determine the prevalence of factor V Leiden in a Canadian blood donor population.
DESIGN: Cross-sectional laboratory study.
SETTING: Hamilton Centre of the Canadian Red Cross Society. PARTICIPANTS: Volunteer donors who attended Hamilton Centre blood donor clinics over a 4-day period in August 1994; blood samples from 356 people were evaluable. OUTCOME MEASURES: Presence of factor V Leiden.
RESULTS: Factor V Leiden was detected in 19 of the 356 people, for a prevalence rate of 5.3% (95% confidence interval 3.0% to 7.6%). All 19 people were shown to be heterozygous for the mutation.
CONCLUSION: Factor V Leiden is common in the Canadian population. Its prevalence is similar to that reported in other Western countries. These data are relevant in the clinical management of patients at risk for venous thrombosis and those with recurrent thrombotic disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8705907      PMCID: PMC1487985     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  19 in total

Review 1.  Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis.

Authors:  R M Bertina; P H Reitsma; F R Rosendaal; J P Vandenbroucke
Journal:  Thromb Haemost       Date:  1995-07       Impact factor: 5.249

2.  Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V.

Authors:  J Voorberg; J Roelse; R Koopman; H Büller; F Berends; J W ten Cate; K Mertens; J A van Mourik
Journal:  Lancet       Date:  1994-06-18       Impact factor: 79.321

3.  Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis.

Authors:  B Zöller; B Dahlbäck
Journal:  Lancet       Date:  1994-06-18       Impact factor: 79.321

4.  Bayesian analysis using Fourier transforms of thallium-201 scintiscans to predict the presence of coronary artery disease.

Authors:  W R Tzall; R R Sciacca; D K Blood; D M McCarthy; P J Cannon
Journal:  Am J Cardiol       Date:  1984-08-01       Impact factor: 2.778

5.  Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.

Authors:  J P Vandenbroucke; T Koster; E Briët; P H Reitsma; R M Bertina; F R Rosendaal
Journal:  Lancet       Date:  1994-11-26       Impact factor: 79.321

6.  Resistance to activated protein C as a basis for venous thrombosis.

Authors:  P J Svensson; B Dahlbäck
Journal:  N Engl J Med       Date:  1994-02-24       Impact factor: 91.245

7.  Anticoagulant protein C pathway defective in majority of thrombophilic patients.

Authors:  J H Griffin; B Evatt; C Wideman; J A Fernández
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

8.  Mutation in blood coagulation factor V associated with resistance to activated protein C.

Authors:  R M Bertina; B P Koeleman; T Koster; F R Rosendaal; R J Dirven; H de Ronde; P A van der Velden; P H Reitsma
Journal:  Nature       Date:  1994-05-05       Impact factor: 49.962

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.

Authors:  T Koster; F R Rosendaal; H de Ronde; E Briët; J P Vandenbroucke; R M Bertina
Journal:  Lancet       Date:  1993 Dec 18-25       Impact factor: 79.321

View more
  9 in total

1.  Thrombus stability explains the factor V Leiden paradox: a mouse model.

Authors:  S A Shaya; R J Westrick; P L Gross
Journal:  Blood Adv       Date:  2019-11-12

Review 2.  Humans, mice, and mechanisms of intestinal atresias: a window into understanding early intestinal development.

Authors:  Peter F Nichol; Amy Reeder; Robert Botham
Journal:  J Gastrointest Surg       Date:  2010-11-30       Impact factor: 3.452

3.  Race differences in the prevalence of the factor V Leiden mutation in Kuwaiti nationals.

Authors:  Ali A Dashti; Mehrez M Jadaon
Journal:  Mol Biol Rep       Date:  2010-11-21       Impact factor: 2.316

4.  Prevalence of factor V Leiden in south Tunisian blood donors.

Authors:  Lobna Maalej; Basma Hadjkacem; Ikram Ben Amor; Mariem Smaoui; Ali Gargouri; Jalel Gargouri
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

5.  Prevalence of resistence to activated protein C (APC-resistance) in blood donors in Kosovo.

Authors:  Ymer Mekaj; Bukurije Zhubi; Hakif Hoxha; Remzije Belegu; Agon Mekaj; Ermira Miftari; Mazllum Belegu
Journal:  Bosn J Basic Med Sci       Date:  2009-11       Impact factor: 3.363

6.  The prevalence of Factor V Leiden, prothrombin G20210A, MTHFR C677T and MTHFR A1298C mutations in healthy Turkish population.

Authors:  M Ekim; H Ekim; Y K Yılmaz
Journal:  Hippokratia       Date:  2015 Oct-Dec       Impact factor: 0.471

7.  Evaluation of a high throughput method for the detection of mutations associated with thrombosis and hereditary hemochromatosis in Brazilian blood donors.

Authors:  Vivian Dionisio Tavares Niewiadonski; Juliana Vieira Dos Santos Bianchi; Cesar de Almeida-Neto; Nelson Gaburo; Ester Cerdeira Sabino
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

8.  Prevalence and role of antithrombin III, protein C and protein S deficiencies and activated protein C resistance in Kosovo women with recurrent pregnancy loss during the first trimester of pregnancy.

Authors:  Ymer Mekaj; Shefqet Lulaj; Fetie Daci; Naser Rafuna; Ermira Miftari; Hakif Hoxha; Xhemile Sllamniku; Agon Mekaj
Journal:  J Hum Reprod Sci       Date:  2015 Oct-Dec

9.  Prevalence of thrombophilia-associated genetic risk factors in blood donors of a regional hospital in southern Brazil.

Authors:  Jéssica Dick-Guareschi; Juliana Cristine Fontana; Maria Teresa Vieira Sanseverino; Francyne Kubaski; Leo Sekine; Nanci Félix Mesquita; Tor Gunnar Hugo Onsten; Sandra Leistner-Segal
Journal:  Hematol Transfus Cell Ther       Date:  2021-03-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.